Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2019, specifically dated July 29, 2019. The report details a strategic regulatory milestone for ViiV Healthcare, a global specialist HIV company majority-owned by GSK (with Pfizer Inc. and Shionogi Limited as shareholders). The filing announces the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for an investigational, once-monthly, injectable HIV treatment regimen.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a regulatory announcement regarding clinical development and product approval rather than a financial earnings report.
Material Changes and Developments
The primary material change reported is the submission of the MAA to the EMA for the combination of cabotegravir and rilpivirine. Key developments include:
- Regulatory Submission: Submission of the MAA to the EMA for the first monthly, injectable treatment for HIV-1 infection in adults with suppressed viral load.
- Product Composition: The regimen consists of ViiV Healthcare's investigational cabotegravir and Janssen's investigational long-acting rilpivirine, administered as intramuscular injections every four weeks.
- Clinical Basis: The application is supported by Phase III ATLAS and FLAIR pivotal trials involving over 1,100 patients across 16 countries.
- Efficacy Results: The studies demonstrated that the monthly injectable regimen was as effective as the standard daily, 3-drug oral regimen in maintaining viral suppression over 48 weeks.
- US Regulatory Status: A New Drug Application (NDA) was previously submitted to the US FDA in April 2019. In June 2019, the FDA granted Priority Review Designation with an expected action date of December 29, 2019.
Outlook, Risks, and Management Commentary
Management Commentary: Deborah Waterhouse, CEO of ViiV Healthcare, stated that if approved, this long-acting injectable regimen could change the frequency of therapy from 365 days per year to just 12 doses, offering a "first-of-its-kind" treatment option. Kimberly Smith, M.D., Head of Global Medical Research and Strategy, emphasized the commitment to innovative options for managing HIV.
Outlook: ViiV Healthcare and Janssen plan to submit additional regulatory applications to other agencies in the coming months. The company aims to deliver this therapy to patients in Europe following the EMA review.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in GSK's 2018 Annual Report on Form 20-F. Specific safety risks associated with the companion drug EDURANT (rilpivirine) include severe skin rash, allergic reactions, liver enzyme changes, depression, and immune reconstitution syndrome. Cabotegravir remains investigational and is not yet approved by any regulatory authority.
Investor Verification Checklist
- Verify the expected FDA action date of December 29, 2019, for the US NDA submission.
- Monitor the EMA review timeline and potential approval date for the European market.
- Review the full safety profile and contraindications for the combination therapy, particularly regarding drug interactions with anti-seizure and anti-TB medicines.
- Assess the commercial impact of a monthly injectable regimen versus daily oral therapies on the HIV treatment market.
- Confirm the ownership structure and financial reporting of ViiV Healthcare within GSK's consolidated results.